Global Information
회사소개 | 문의 | 비교리스트

미국의 제약 산업 분석과 동향

U.S. Pharmaceuticals Industry Analysis and Trends 2023

리서치사 NAVADHI Market Research Pvt Ltd
발행일 2019년 03월 상품 코드 814622
페이지 정보 영문 255 Pages
가격
US $ 3,500 ₩ 4,371,000 Single User License - PDF
US $ 4,500 ₩ 5,620,000 Enterprise License - PDF


미국의 제약 산업 분석과 동향 U.S. Pharmaceuticals Industry Analysis and Trends 2023
발행일 : 2019년 03월 페이지 정보 : 영문 255 Pages

미국의 제약(Pharmaceuticals) 산업에 대해 조사 분석했으며, 시장 개요, 시장 예측, 성장 촉진요인·성장 저해요인, 관련 리스크, 주요 기업 개요, 경쟁 상황 등에 대한 체계적인 정보를 제공합니다.

제1장 주요 요약

제2장 미국의 제약 시장 서론

제3장 미국의 제약 시장 수요

  • 미국의 인구 증가와 고령화
  • 빈곤층과 중산층의 소득 수준 향상

제4장 미국의 제약 시장 예측

  • 북미의 제약 시장 예측

제5장 미국의 제약 시장 성장 촉진요인과 저해요인

제6장 미국의 제약 시장 관련 리스크

  • 특허 만료와 보호 손실 리스크
  • 신제품의 상업적 성공 리스크
  • 연구개발 대처 실패 리스크
  • 의약품 가격 관리 리스크
  • 새로운 법률 및 규제 준수 불이행 리스크
  • 복잡한 제조 공정에서의 품질 관리 리스크
  • 사이버 공격과 데이터 유출 리스크
  • 변동하는 환율 및 금리 리스크
  • 불안정한 세계 정치 및 경제 상황 리스크

제7장 미국의 제약 시장 관련 정부기관 및 업계단체

  • FDA
  • AAPS
  • PhRMA
  • AAM

제8장 미국의 제약 시장 상위 10개사 개요

  • Pfizer Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • AbbVie Inc.
  • Amgen Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Gilead Sciences Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company

제9장 미국의 제약 시장 경쟁 상황

제10장 미국의 제약 시장 분석

  • Porter's Five Forces 분석
  • SWOT 분석

제11장 미국의 제약 시장 현재와 향후 동향

  • 희귀의약품
  • 생물제제 및 바이오시밀러
  • 현재 동향
KSM 19.04.11

U.S. (United States) pharmaceutical market is the largest pharmaceuticals market in the world and accounted for more than 40% global pharmaceuticals sales in 2017. USA pharmaceuticals market is expected to grow in the upcoming years despite recent slowdown due to price erosion in U.S. generics pharmaceuticals market, delay in approval of complex generics by US FDA (United States Food and Drug Administration) and Government's talks of drug price control mechanism like other major pharmaceutical markets. The reasons are simple: aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases.

“U.S. pharmaceuticals market is expected to be worth USD 685.45 billion by 2023.”

As per NAVADHI Market Research, the U.S. pharmaceutical industry will we worth USD 685.45 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

U.S. is expected to retain it's leading position in the global pharmaceuticals market with market share of 43.72% in 2023 improving on it's market share compared to 2017.

This growth is fuelled by the growing and ageing population in U.S. More than 15% of U.S. population is above 65 years of age and this number is expected to rise by 2023. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of U.S. pharma industry. The income level of average American is expected to rise by 3.21% CAGR by 2023, due to rising employment levels and stable economic conditions. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and speciality diseases. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies and bioelectronics & implantables has attracted investments in the industry by even non-pharma companies like Facebook, Qualcomm etc. which is also driving the U.S. pharmaceuticals industry growth.

On the other hand, United States government's plan to implement of cost control policies along with tightening of rules by government like delay in approval of complex generics and price erosion in U.S. generics pharmaceuticals market are expected to impact the growth prospect of the U.S. pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the U.S. pharma market as new drugs revenue form large part of pharma firm's revenue due to exclusivity of the drug.

Navadhi has provided detailed company profiles including their position in U.S pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for top 10 companies in U.S. pharmaceuticals market by their pharmaceuticals revenue namely: Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Amgen, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., Sanofi S.A and Bristol-Myers Squib

Scope of the U.S. Pharmaceuticals Industry Analysis and Trends 2023 Report:

  • This report provides detailed information about United States pharmaceuticals market including future market forecasts up to 2023.
  • This report identifies the need for focusing on U.S. pharmaceuticals market
  • The report identifies the growth drivers and inhibitors for U.S. pharmaceuticals market.
  • The report identifies various risks associated with U.S. pharmaceuticals market.
  • This report has detailed profiles of top 10 companies in U.S. pharmaceuticals market by their pharmaceutical revenue covering their position in pharmaceuticals value chain, business strategy, financial performance, future forecasts and SWOT analysis.
  • This report provides competitive landscape among top 10 pharmaceutical companies in U.S. market.
  • This report provides Porter's Five Forces analysis for U.S. pharmaceuticals market.
  • This report provides SWOT (strengths, weakness, opportunities and threats) analysis for U.S. pharmaceuticals market.
  • This report provides information about current and future trends for U.S. pharmaceuticals market.

COMPANIES COVERED:

  • 1. Pfizer Inc.
  • 2. Johnson & Johnson
  • 3. Roche Holding AG
  • 4. AbbVie Inc.
  • 5. Amgen
  • 6. Novartis AG
  • 7. Merck & Co., Inc.
  • 8. Gilead Sciences, Inc.
  • 9. Sanofi S.A
  • 10. Bristol-Myers Squib

Table of Contents

1. Executive Summary

  • Scope of the U.S. Pharmaceuticals Industry Analysis and Trends 2023 Report
  • Research Methodology

2. Introduction of U.S. Pharmaceuticals Market

  • Key Product Terms Used in Pharmaceuticals Industry
  • Pharmaceuticals
  • Innovative Drugs
  • Orphan Drugs
  • Generic Drugs
  • Commodity Generic Drugs
  • Branded Generic Drugs
  • Biologics
  • Biosimilars
  • Over-the-counter (OTC) Drugs
  • Active Pharmaceutical Ingredients (APIs)
  • Excipients
  • Research and Development (R&D) Phases of Pharmaceuticals Industry
  • Industry-Wise Research and Development (R&D) Investment
  • Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
  • U.S. Pharmaceuticals Industry Value Chain Analysis

3. Need for U.S. Pharmaceuticals Market

  • Rising & Ageing U.S. Population
  • Increasing Income Levels of Poor & Middle-Class Families

4. Forecast for U.S. Pharmaceuticals Market 2023

  • 4.1. Forecast for North America Pharmaceuticals Market 2018-2023
    • 4.1.1. Forecast for U.S. Pharmaceuticals Market 2018-2023

5. Growth Drivers and Inhibitors for U.S. Pharmaceuticals Market

6. Risks Associated with U.S. Pharmaceuticals Market

  • 6.1. Risk of Patent Expiry and Loss of Intellectual Property Protection
  • 6.2. Risk of Commercial Success of New Products
  • 6.3. Risk of Failed Research and Development Effort
  • 6.4. Risk of Drug Price Controls
  • 6.5. Risk of Failure to Comply with New Laws and Regulations
  • 6.6. Risk of Quality Control During Complex Manufacturing Process
  • 6.7. Risk of Cyber-Attacks and Data Breach
  • 6.8. Risk of Volatile Currency Exchange Rates and Interest Rates
  • 6.9. Risk of Unstable Global Political and Economic Conditions

7. Government Bodies and Industry Associations Related to U.S. Pharmaceuticals Market

  • 7.1. Food and Drug Administration (FDA)
  • 7.2. American Association of Pharmaceutical Scientists (AAPS)
  • 7.3. Pharmaceutical Research and Manufacturers of America (PhRMA)
  • 7.4. Association for Accessible Medicines (AAM)

8. Profile of Top 10 Companies in U.S. Pharmaceuticals Market

  • 8.1. Pfizer Inc.
    • 8.1.1. Company Profile
    • 8.1.2. Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.1.3. Pfizer Inc.: Financial Performance
      • 8.1.3.1. Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
      • 8.1.3.2. Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
      • 8.1.3.3. Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
    • 8.1.4. Pfizer Inc.: Business Strategy
      • 8.1.4.1. Product Level Strategy
    • 8.1.5. SWOT Analysis of Pfizer Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.2. Johnson & Johnson
    • 8.2.1. Company Profile
    • 8.2.2. Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
    • 8.2.3. Johnson & Johnson Financial Performance
      • 8.2.3.1. Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)
      • 8.2.3.2. Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)
      • 8.2.3.3. Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)
      • 8.2.3.4. Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)
    • 8.2.4. Johnson & Johnson: Business Strategy
      • 8.2.4.1. Product Level Business Strategy
    • 8.2.5. Johnson & Johnson's Pharmaceutical Division Growth Drivers
    • 8.2.6. SWOT Analysis of Johnson & Johnson
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.3. Roche Holding AG
    • 8.3.1. Company Profile
    • 8.3.2. Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
    • 8.3.3. Roche Holding AG: Financial Performance
      • 8.3.3.1. Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
      • 8.3.3.2. Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
      • 8.3.3.3. Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
      • 8.3.3.4. Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
      • 8.3.3.5. Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
    • 8.3.4. Roche Holding AG: Business Strategy
      • 8.3.4.1. Product Level Strategy
    • 8.3.5. SWOT Analysis of Roche Holding AG
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 8.3.6. Key Customers of Roche Holding AG
  • 8.4. AbbVie Inc.
    • 8.4.1. Company Profile
    • 8.4.2. AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.4.3. AbbVie Inc.: Financial Performance
      • 8.4.3.1. AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
      • 8.4.3.2. AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
      • 8.4.3.3. AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
    • 8.4.4. AbbVie Inc.: Business Strategy
      • 8.4.4.1. Product Level Strategy
    • 8.4.5. SWOT Analysis of AbbVie Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.5. Amgen Inc.
    • 8.5.1. Company Profile
    • 8.5.2. Amgen Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.5.3. Amgen Inc. and Company: Financial Performance
      • 8.5.3.1. Amgen Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
      • 8.5.3.2. Amgen Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
      • 8.5.3.3. Amgen Inc.: Division-Wise Revenue FY 2018 (in USD billion)
      • 8.5.3.4. Amgen Inc.: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
      • 8.5.3.5. Amgen Inc.: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
    • 8.5.4. Amgen Inc.: Business Strategy
      • 8.5.4.1. Product Level Strategy
    • 8.5.5. SWOT Analysis of Amgen Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.6. Novartis AG
    • 8.6.1. Company Profile
    • 8.6.2. Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
    • 8.6.3. Novartis AG: Financial Performance
      • 8.6.3.1. Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
      • 8.6.3.2. Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
      • 8.6.3.3. Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
    • 8.6.4. Novartis AG: Business Strategy
    • 8.6.5. SWOT Analysis of Novartis AG
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.7. Merck & Co., Inc.
    • 8.7.1. Company Profile
    • 8.7.2. Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.7.3. Merck & Co., Inc.: Financial Performance
      • 8.7.3.1. Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
      • 8.7.3.2. Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
      • 8.7.3.3. Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
      • 8.7.3.4. Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
    • 8.7.4. Merck & Co., Inc.: Business Strategy
      • 8.7.4.1. Product Level Strategy
    • 8.7.5. SWOT Analysis of Merck & Co., Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.8. Gilead Sciences Inc.
    • 8.8.1. Company Profile
    • 8.8.2. Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.8.3. Gilead Sciences, Inc.: Financial Performance
    • 8.8.4. Gilead Sciences, Inc.: Geography wise Performance
    • 8.8.5. Gilead Sciences, Inc.: Business Strategy
    • 8.8.6. SWOT Analysis of Gilead Sciences, Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.9. Sanofi S.A.
    • 8.9.1. Company Profile
    • 8.9.2. Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.9.3. Sanofi S.A.: Financial Performance
      • 8.9.3.1. Sanofi S.A.: Geography-Wise Revenue
    • 8.9.4. Sanofi S.A.: Business Strategy
      • 8.9.4.1. Sanofi S.A. Revenue by Global Business Units (GBU's)
      • 8.9.4.2. Sanofi S.A. Revenue by Global Franchise
    • 8.9.5. SWOT Analysis of Sanofi S.A.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 8.9.6. Sanofi's TOP 10 Blockbusters Drugs Revenue in FY 2018 (in Euro millions)
  • 8.10. Bristol-Myers Squibb Company
    • 8.10.1. Company Profile
    • 8.10.2. Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
    • 8.10.3. Bristol-Myers Squibb Company: Financial Performance
      • 8.10.3.1. Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019 (in USD billion)
      • 8.10.3.2. Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018 (in USD billion)
      • 8.10.3.3. Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
    • 8.10.4. Bristol-Myers Squibb Company: Business Strategy
      • 8.10.4.1. Product Level Strategy
    • 8.10.5. SWOT Analysis of Bristol-Myers Squibb Company
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats

9. Competitive Landscape in U.S. Pharmaceuticals Market

  • 9.1. Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue
  • 9.2. Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Global Pharmaceuticals Revenue
  • 9.3. Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by United States Pharmaceuticals Revenue
  • 9.4. Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Development (R&D) Expenditure
  • 9.5. Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earning Per Share (EPS)
  • 9.6. Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
  • 9.7. Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue Forecast
  • 9.8. Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Top 3 Product Revenues

10. Analysis of U.S. Pharmaceuticals Market

  • 10.1. Porter's Five Forces Analysis of U.S. Pharmaceuticals Market
  • 10.2. SWOT Analysis of U.S. Pharmaceuticals Market
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats

11. Current and Future Trends in U.S. Pharmaceuticals Market

  • Orphan Drugs
  • Biologics and Biosimilars
  • Current Trends
    • 1. Increasing Severity of Drug Price Controls
    • 2. Greater Focus on Rare Diseases / Orphan Drugs
    • 3. Increasing Development of Nucleic Acids as Therapeutics
    • 4. Increasing Focus on Cell Therapy
    • 5. Implantables (Bioelectronics) and Electroceuticals are Expected to Become Mainstream
    • 6. Use of 3D Printing to Reduce Cost and Improve Production Efficiency of Biologics
    • 7. Increasing Use of Big Data and Artificial Intelligence (AI) in Drug Discovery
  • List of Exhibits
  • Notes
  • Company Information

List of Exhibits

  • Exhibit 2.1: Research and Development Phases of Pharmaceuticals Industry
  • Exhibit 2.2: Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
  • Exhibit 2.3: Phase-Wise Research and Development Investment in Pharmaceuticals Industry
  • Exhibit 2.4: U.S. Pharmaceuticals Industry Value Chain Analysis
  • Exhibit 3.1: Country-Wise Population Forecast 2016-2023 (in millions)
  • Exhibit 3.2: Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
  • Exhibit 4.1: Forecast for North America Pharmaceuticals Market 2018-2023 (in USD billion)
  • Exhibit 4.2: Country-wise Market Share in North America Pharmaceuticals Market in 2017 (in %)
  • Exhibit 4.3: Population Forecast for U.S. 2016-2023 (in millions)
  • Exhibit 4.4: U.S. Pharmaceuticals Market Analysis
  • Exhibit 4.5: Forecast for U.S. Pharmaceuticals Market 2018-2023 (in USD billion)
  • Exhibit 5.1: Growth Drivers and Inhibitors for U.S. Pharmaceuticals Market
  • Exhibit 6.1: Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
  • Exhibit 7.1: Key Information of FDA
  • Exhibit 7.2: Contact details of FDA
  • Exhibit 7.3: Key Information of AAPS
  • Exhibit 7.4: Contact details of AAPS
  • Exhibit 7.5: Key Information of PhRMA
  • Exhibit 7.6: Contact details of PhRMA
  • Exhibit 7.7: List of PhRMA Members
  • Exhibit 7.8: Key information of AAM
  • Exhibit 7.9: Contact details of AAM
  • Exhibit 7.10: List of AAM Members
  • Exhibit 8.1: Key Information of Pfizer Inc.
  • Exhibit 8.2: Contact information of Pfizer Inc.
  • Exhibit 8.3: Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.4: Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.5: Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
  • Exhibit 8.6: Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
  • Exhibit 8.7: Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
  • Exhibit 8.8: Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)j
  • Exhibit 8.9: SWOT Analysis of Pfizer Inc.
  • Exhibit 8.10: Key Information of Johnson & Johnson
  • Exhibit 8.11: Contact information of Johnson & Johnson
  • Exhibit 8.12: Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.13: Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.14: Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
  • Exhibit 8.15: Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.16: Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.16: Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.17: Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.18: Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.19: Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.20: Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
  • Exhibit 8.21: SWOT Analysis of Johnson & Johnson
  • Exhibit 8.22: Key Information of Roche Holding AG
  • Exhibit 8.23: Contact Information of Roche Holding AG
  • Exhibit 8.24: Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
  • Exhibit 8.25: Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
  • Exhibit 8.26: Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
  • Exhibit 8.27: Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
  • Exhibit 8.28: Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
  • Exhibit 8.29: Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
  • Exhibit 8.30: County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
  • Exhibit 8.31: Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
  • Exhibit 8.32: County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
  • Exhibit 8.33: Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
  • Exhibit 8.34: Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
  • Exhibit 8.35: Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)
  • Exhibit 8.36: SWOT Analysis of Roche Holding AG
  • Exhibit 8.37: Roche Holding AG Pharmaceuticals Product Pipeline
  • Exhibit 8.38: Key information of AbbVie Inc.
  • Exhibit 8.39: Contact Information of AbbVie. Inc.
  • Exhibit 8.40: AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.41: Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.42: Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)
  • Exhibit 8.43: Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
  • Exhibit 8.44: Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
  • Exhibit 8.45: Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)
  • Exhibit 8.46: SWOT Analysis of AbbVie Inc.
  • Exhibit 8.47: Key information of Amgen Inc.
  • Exhibit 8.48: Contact details of Amgen Inc.
  • Exhibit 8.49: Amgen Inc. in Global Pharmaceuticals Manufacturing value chain
  • Exhibit 8.50: Revenue of Amgen Inc. FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.51: Revenue Growth of Amgen Inc FY 2014-FY 2019 (in %)
  • Exhibit 8.52: Geography-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
  • Exhibit 8.53: United States Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.54: United States Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
  • Exhibit 8.55: Rest of World Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.56: Rest of World Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
  • Exhibit 8.57: Division-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
  • Exhibit 8.58: Pharmaceuticals Division Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.59: Other Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.60: Geography-Wise Pharmaceuticals Revenue of Amgen Inc in FY 2018 (in USD billion)
  • Exhibit 8.61: United States Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.62: Rest of World Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.63: Brand-Wise Pharmaceuticals Revenue of Amgen Inc FY 2018 (in USD billion)
  • Exhibit 8.64: SWOT Analysis of Amgen Inc
  • Exhibit 8.65: Key Information of Novartis AG
  • Exhibit 8.66: Contact Information of Novartis AG
  • Exhibit 8.67: Novartis AG in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.68: Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.69: Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
  • Exhibit 8.70: Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
  • Exhibit 8.71: Therapy and Geography Area-Wise Revenue of Novartis AG FY 2018 (in USD million)
  • Exhibit 8.72: Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
  • Exhibit 8.73: Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
  • Exhibit 8.74: Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
  • Exhibit 8.75: Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
  • Exhibit 8.76: 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
  • Exhibit 8.77: SWOT Analysis of Novartis AG
  • Exhibit 8.78: Key Information of Merck & Co.
  • Exhibit 8.79: Contact Information of Merck & Co.
  • Exhibit 8.80: Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.81: Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.82: Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
  • Exhibit 8.83: Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.84: Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.85: Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.86: Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.87: Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.88: Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
  • Exhibit 8.89: SWOT Analysis of Merck & Co., Inc.
  • Exhibit 8.90: Key Information of Gilead Sciences, Inc.
  • Exhibit 8.91: Contact Information of Gilead Sciences, Inc.
  • Exhibit 8.92: Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.93: Gilead Sciences, Inc. Revenue 2014-2019 (in USD billion)
  • Exhibit 8.94: Year-wise Gilead Sciences, Inc. Revenue Growth 2014-19 (in %)
  • Exhibit 8.95: Gilead Sciences, Inc. Geography Wise Revenue Share in (%) 2018
  • Exhibit 8.96: Gilead Sciences, Inc. Geography Wise Revenue in USD Billion (2016 - 2018)
  • Exhibit 8.97: Gilead Sciences, Inc. Business Segment Revenue Share 2018
  • Exhibit 8.98: Gilead Sciences, Inc. Segment wise Revenue in USD Billion (2016- 2018)
  • Exhibit 8.99: Gilead Sciences, Inc. Revenue from HIV Product Sales (2016-2018)
  • Exhibit 8.100: Gilead Sciences, Inc. HIV Product Sales by Medicine in USD Million (2018)
  • Exhibit 8.101: Gilead Sciences, Inc. Revenue from HCV Product Sales (2016-2018)
  • Exhibit 8.102: Gilead Sciences, Inc. HCV Product Sales by Medicine in USD Million (2018)
  • Exhibit 8.103: Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales (2016-2018)
  • Exhibit 8.104: Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales by Medicine in USD Million (2018)
  • Exhibit 8.105: Gilead Sciences, Inc. Revenue from Yescarta® Sales (2017-2018)
  • Exhibit 8.106: SWOT Analysis of Gilead Sciences, Inc.
  • Exhibit 8.107: Key Information of Sanofi S.A.
  • Exhibit 8.108: Contact Information of Sanofi S.A.
  • Exhibit 8.109: Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.110: Sanofi S.A. Revenue FY2014-2019 (in Euro billion)
  • Exhibit 8.111: Year-wise Sanofi S.A. Growth 2014-19 (in %)
  • Exhibit 8.112: Geography-wise Sanofi S.A. Revenue Share FY 2018 (in %)
  • Exhibit 8.113: Geography-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
  • Exhibit 8.114: Global Business Units (GBU's)-wise Sanofi S.A. Revenue FY 2018 (in %)
  • Exhibit 8.115: Global Business Units (GBU's)-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
  • Exhibit 8.116: Global Franchise-wise Sanofi S.A. Revenue FY 2018 (in %)
  • Exhibit 8.117: Global Franchise-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
  • Exhibit 8.118: Sanofi S.A. Speciality Care Franchise Revenue FY 2018 (in %)
  • Exhibit 8.119: Sanofi S.A. Speciality Care Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.120: Sanofi S.A. Diabetes and Cardiovascular (DCV) Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.121: Sanofi S.A. Established Rx Products Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.122: Sanofi S.A. Consumer Healthcare (CHC) Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.123: Sanofi S.A. Generic Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.124: Sanofi S.A. Vaccines Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.125: SWOT Analysis of Sanofi S.A.
  • Exhibit 8.126: Top 10 Blockbuster Drug Revenue of Sanofi (in Euro millions)
  • Exhibit 8.127: Key Information of Bristol-Myers Squib Company
  • Exhibit 8.128: Contact Information of Bristol-Myers Squib Company
  • Exhibit 8.129: Bristol-Myers Squib Company in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.130: Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.131: Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)
  • Exhibit 8.132: Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)
  • Exhibit 8.133: United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.134: United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
  • Exhibit 8.135: Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.136: Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
  • Exhibit 8.137: Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.138: Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
  • Exhibit 8.139: Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.140: Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
  • Exhibit 8.141: Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)
  • Exhibit 8.142: SWOT Analysis of Bristol-Myers Squib Company
  • Exhibit 9.1: Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue for FY2018 (in USD billion)
  • Exhibit 9.2: Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
  • Exhibit 9.3: Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by United States Pharmaceuticals Revenue for FY2018 (in USD billion)
  • Exhibit 9.4: Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
  • Exhibit 9.5: Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
  • Exhibit 9.6: Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
  • Exhibit 9.7: Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue Forecast for FY2019 (in USD billion)
  • Exhibit 9.8: Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by 3 Blockbuster Product Revenue for FY2018 (in USD billion)
  • Exhibit 10.1: Porter's Five Forces Analysis for U.S. Pharmaceuticals Market
  • Exhibit 10.2: SWOT Analysis for U.S. Pharmaceuticals Market
Back to Top
전화 문의
F A Q